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Adenosine receptors A2A are a class of purinergic receptors largely expressed in 
dopamine (DA)-rich areas of the central nervous system. In particular, they are abundant 
within basal ganglia, where they modulate the activity of various neurotransmitters, 
including DA.Despite the lack of knowledge on their fine physiological mechanisms, 
tt is worth to mention that A2A antagonists prevent neuronal death and dyskenisia in 
Parkinsonism.
A new compound, ATBI-10, bind with high selectivity to A2A receptors with antago-
nist activity. In the present study, by profiting of such an highly selective compound 
we investigated: (i) whether such a novel compound protect DA containing neurons 
against the parkikinsonian neurotoxin 1-methyl-4-phenylpirydinium and the dyskine-
togenic compound methamphetamine. (ii) The cellular mechanisms which are involved 
in these phenomena as a consequence of A2A receptor modulation. We carried out an in 
vitro study using two models of DA neurons PC12 and SH-SY5Y. We found that ATBI-10 
at doses of 16 and 32 nM protects against DA neurotoxicity in all models, being mostly 
effective against MA toxicity (complete prevention). In light of the key role of autophagy 
in modulating the survival of DA neurons we investigated the association between A2A 
receptors and the the autophagic pathway. We found that antagonism at A2A receptors 
produces an increased autophagy (increased LC3-II levels). This effects appear to be 
shared by all A2A antagonists. 
Our data indicate that A2A antagonists are neuroprotective against a vatriety of in-
sults to DA neurons and such an effect appear to be mediated by the enhancement of 
autophagy. We are now evaluating in vitro and in vivo whether endogenous adenosine 
might produce neurodegeneration by activating A2A receptors. These results indicate 
novel therapeutic effects of A2A antagonists and provide evidence on their mechanism 
of action.
